Company intelligence / Profile preview

Pelican Therapeutics

San Antonio, Texas, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Pelican Therapeutics' lead candidate PTX-35 entered Phase 1 clinical trials in June 2020 for patients with advanced solid tumors refractory to standard of care. The trial is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT)[7][9].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesT cell co-stimulatorsFusion proteins
Industry: Biotech

Drug pipeline

1 asset

PTX-25

Pre-clinical

Indications: Cancer

Beyond the preview

Go deeper on Pelican Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelican Therapeutics.

Explore the full profile